cidp ivig

[CIDP]

CIDP study suggests more treatment

Friday 26th September 2008
mental health woman
click here
A study of a treatment for chronic inflammatory demyelinating
neuropathy (CIDP) suggests that 50% of the patients who responded to
treatment with Gamunex (Immune Globulin Intravenous, 10% Caprylate/
Chromatography Purified) required two treatments before they first
exhibited improvements.

Data presented at the American Neurological Association meeting in
Salt Lake City concluded that "further studies in CIDP are warranted
to more clearly define the duration of treatment required to achieve
and maintain maximal response to IVIG therapy."

The study of CIDP � a neurological condition that damages peripheral
nerves and causes progressive muscle weakness in the arms and legs �
was funded by Talecris Biotherapeutics.

Study author Norman Latov, from Cornell University, said: "Our data
suggest that some patients may require more than one treatment course
to achieve clinical response and additional IGIV-C treatments might
clinically benefit a substantial number of CIDP patients."

The data reported at the association meeting is a sub-analysis of a
larger phase III study published in the February 2008 issue of The
Lancet Neurology.

Results of that study were used to support the recent approval of
Gamunex by the US Food and Drug Administration as a treatment for CIDP.

[CIDP]

[CIDP]

http://www.cidpusa.org/P/ivig.htm for information on IVIg